N. Jagannathan

Jun 3, 2024 | nature.com | Wei-Xiang Sin |N. Jagannathan |Xiaolin Wu |Joshua Raymond |Yie Hou Lee |Qingfeng Chen | +3 more

AbstractThe manufacturing of autologous chimaeric antigen receptor (CAR) T cells largely relies either on fed-batch and manual processes that often lack environmental monitoring and control or on bioreactors that cannot be easily scaled out to meet patient demands.